BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

Chinese generic drug for breast, pancreatic, and lung cancer approved in EU market

July 31, 2024 | News

Nanoparticle albumin-bound paclitaxel offers significant advantages for clinical use in oncology



Apexelsin, a generic drug from China been approved by the European Commission. Apexelsinis a generic drug to Bristol Myers Squibb's and Celgene's Abraxane®(Nab-paclitaxel). Apexelsin® is developed by WhiteOak Pharmaceutical B.V. and Kexing Biopharm is in charge of the commercialization of this product out of the US.

Comparatively to solvent-based paclitaxel and liposomal paclitaxel, nanoparticle albumin-bound paclitaxel offers significant advantages for clinical use, providing improved safety and higher patient compliance. Furthermore, ESMO guidelines recommend it as a first-line treatment option for metastatic pancreatic cancer and non-small cell lung cancer (NSCLC), as well as a second-line treatment option for breast cancer.

The approval of albumin-bound paclitaxel by the EU will enhance the company's competitiveness in the international pharmaceutical market. Kexing Biopharm has introduced more than a dozen high-quality Chinese medications to emerging markets, improving accessibility to medicines for local patients. To date, Kexing Biopharm is proceeding with the registration of Apexelsin® in dozens of emerging markets out of Europe. With the successful launch of this product in the EU, Kexing Biopharm will further expand its global sales reach, serving more patients and healthcare providers.